Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Prescription-event monitoring--recent progress and future horizons.

Mann RD.

Br J Clin Pharmacol. 1998 Sep;46(3):195-201. Review. No abstract available.

2.

Prescription-event monitoring: methodology and recent progress.

Rawson NS, Pearce GL, Inman WH.

J Clin Epidemiol. 1990;43(5):509-22.

PMID:
2324790
3.

FDA turns to electronic "sentinel" to flag prescription drug safety problems.

Kuehn BM.

JAMA. 2008 Jul 9;300(2):156-7. doi: 10.1001/jama.300.2.156. No abstract available.

PMID:
18612108
4.

Prescription-event and other forms of epidemiological monitoring of side-effects in the UK.

Dunn N, Mann RD.

Clin Exp Allergy. 1999 Jul;29 Suppl 3:217-39.

PMID:
10444241
5.

Postmarketing surveillance of adverse reactions to drugs.

[No authors listed]

Br Med J (Clin Res Ed). 1984 Apr 14;288(6424):1155-6. No abstract available.

6.

Two UK Government proposals bearing on drug safety.

Griffin JP.

Adverse Drug React Toxicol Rev. 1997 Mar;16(1):1-7. Review. No abstract available.

PMID:
9192053
7.

Wonder vigilance.

Edwards IR.

Drug Saf. 2010 Feb 1;33(2):83-6. doi: 10.2165/11532300-000000000-00000. No abstract available.

PMID:
20088622
8.

Suspected adverse reactions, 2007.

Dyer F, Spagnuolo-Weaver M, Coolees S, Tait A.

Vet Rec. 2008 Jul 19;163(3):69-72. No abstract available.

PMID:
18702197
9.

[Safety of medicinal products and reporting of adverse drug reactions].

Skibicka I, Maciejczyk A.

Neurol Neurochir Pol. 2004 Nov-Dec;38(6):503-10. Review. Polish.

PMID:
15654675
10.

The demise of postmarketing surveillance.

Fletcher AP.

Adverse Drug React Toxicol Rev. 1995 Spring;14(1):7-9. No abstract available.

PMID:
7612783
11.

[Drug safety: from development to clinical use].

Ovchinnikova EA, Gerasimov VB.

Antibiot Khimioter. 2006;51(6):15-22. Review. Russian. No abstract available.

PMID:
17523417
12.

Thoughts on signal detection in pharmacovigilance.

Shakir SA.

Drug Saf. 2007;30(7):603-6. No abstract available.

PMID:
17604411
13.

Prescription-event monitoring and yellow cards.

Inman WH.

Lancet. 1984 Jun 9;1(8389):1301. No abstract available.

PMID:
6145011
14.

Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.

Tomlin A, Reith D, Dovey S, Tilyard M.

Drug Saf. 2012 Sep 1;35(9):733-43. doi: 10.2165/11631970-000000000-00000.

PMID:
22861670
15.

Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.

Fang H, Su Z, Wang Y, Miller A, Liu Z, Howard PC, Tong W, Lin SM.

Clin Pharmacol Ther. 2014 May;95(5):496-8. doi: 10.1038/clpt.2014.17.

16.
17.

Drug makers' adverse event reports are often incomplete, US report finds.

McCarthy M.

BMJ. 2015 Feb 4;350:h651. doi: 10.1136/bmj.h651. No abstract available.

PMID:
25652561
18.

[Drug information and prescription guidance: role of regional centers of pharmacovigilance].

Blayac JP, Haramburu F, Lerebours S, Vial T.

Presse Med. 2000 Jan 22;29(2):115-8. French.

PMID:
10682043
19.

Adverse drug reaction reporting systems: the United Kingdom and the United States.

Scott HD, Thacher A, Rosenbaum SE, Waters WJ Jr, Green M.

R I Med J. 1988 May;71(5):179-84. No abstract available.

PMID:
3387803
20.

Improving drug safety monitoring.

Karande S, Gogtay NJ, Kshirsagar NA.

Indian Pediatr. 2003 Dec;40(12):1167-75. Review.

Items per page

Supplemental Content

Support Center